Biofunctionalized targeted nanoparticles for therapeutic applications
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The development of nanoparticles for the delivery of therapeutic agents has introduced new opportunities for the improvement of medical treatment. Recent efforts have focused on developing targeted nanoparticles, which are formulated by (for therapeutic delivery) functionalizing nanoparticle surfaces with targeting molecules, such as antibodies, peptides, small molecules and oligonucleotides. OBJECTIVES: To review the state of targeted nanoparticles development. METHODS: The authors discuss the nanoparticle platforms for therapeutic delivery, targeting molecules and the biofunctionalized targeted nanoparticles currently in development. RESULTS/CONCLUSIONS: Biofunctionalized targeted nanoparticles have demonstrated exciting results in preclinical studies. With continued improvements, they may fulfill their potential as therapeutics carriers that can deliver the maximum dose to diseased tissue while minimizing effects on normal cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
Hirsch, L. R., Stafford, R. J., Bankson, J. A., Sershen, S. R., Rivera, B., Price, R. E., Hazle, J. D., Halas, N. J., & West, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232479100 · Cited by 3,955
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Designing materials for biology and medicine
Langer, R., & Tirrell, D. A. (2004) · Nature · doi:10.1038/nature02388 · Cited by 3,198 · cited 1×
“Furthermore, the rate of drug release can be controlled by modification of the polymer side chain, development of novel polymers or synthesis of copolymers [19-23] .”
BackgroundBiodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
About Dendrimers: Structure, Physical Properties, and Applications
Bosman, A. W., Janssen, H. M., & Meijer, E. W. (1999) · Chemical Reviews · doi:10.1021/cr970069y · Cited by 2,343
(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Dendrimers in biomedical applications—reflections on the field
SVENSON, S., & TOMALIA, D. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.018 · Cited by 1,919
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910 · cited 2×
“Specifically, the hydrophobic blocks form the core to minimize their exposure to aqueous surroundings while the hydrophilic blocks form the corona-like shell to stabilize the core [16] .”
BackgroundLanger, R. (1990) · Science · doi:10.1126/science.2218494 · Cited by 1,778
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Self-citationThe emerging nanomedicine landscape
Wagner, V., Dullaart, A., Bock, A.-K., & Zweck, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1006-1211 · Cited by 1,630
Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00009-3 · Cited by 1,474 · cited 1×
“Poly( d , l -lactic acid), poly( d , l -glycolic acid), poly( ε -caprolactone), and their copolymers at various molar ratios diblocked or multiblocked with PEG are the most commonly used biodegradable polymers, while PEG is the polymer used most commonly to engineer the polymeric micelle surface [16,24,25] .”
BackgroundIn Vitro Selection of Functional Nucleic Acids
Wilson, D. S., & Szostak, J. W. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.611 · Cited by 1,206
Polymers for the sustained release of proteins and other macromolecules
LANGER, R., & FOLKMAN, J. (1976) · Nature · doi:10.1038/263797a0 · Cited by 1,182
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Folate-mediated delivery of macromolecular anticancer therapeutic agents
Lu, Y., & Low, P. S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00042-x · Cited by 941
Kukowska-Latallo, J. F., Candido, K. A., Cao, Z., Nigavekar, S. S., Majoros, I. J., Thomas, T. P., Balogh, L. P., Khan, M. K., & Baker, J. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3921 · Cited by 912
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Self-citationEllington, A. D., & Szostak, J. W. (1992) · Nature · doi:10.1038/355850a0 · Cited by 856
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711714105 · Cited by 715
Self-citationHurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Hirsch, L. R., Gobin, A. M., Lowery, A. R., Tam, F., Drezek, R. A., Halas, N. J., & West, J. L. (2006) · Annals of Biomedical Engineering · doi:10.1007/s10439-005-9001-8 · Cited by 497
Controlled assembly of dendrimer-like DNA
Li, Y., Tseng, Y. D., Kwon, S. Y., d'Espaux, L., Bunch, J. S., McEuen, P. L., & Luo, D. (2004) · Nature Materials · doi:10.1038/nmat1045 · Cited by 482
Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477
Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo
Deguchi, J.-O., Aikawa, M., Tung, C.-H., Aikawa, E., Kim, D.-E., Ntziachristos, V., Weissleder, R., & Libby, P. (2006) · Circulation · doi:10.1161/circulationaha.106.619056 · Cited by 419
Stealth PLA-PEG nanoparticles as protein carriers for nasal administration
Tobío, M., Gref, R., Sánchez, A., Langer, R., & Alonso, M. J. (1998) · Pharmaceutical Research · doi:10.1023/a:1011922819926 · Cited by 402
Lee, J. F., Stovall, G. M., & Ellington, A. D. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.03.015 · Cited by 398
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez-Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., De Baetselier, P., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 382
Controlled and modulated release of basic fibroblast growth factor
Edelman, E. R., Mathiowitz, E., Langer, R., & Klagsbrun, M. (1991) · Biomaterials · doi:10.1016/0142-9612(91)90107-l · Cited by 363
Hu, S., Shively, L., Raubitschek, A. A., Sherman, M. A., Williams, L. E., Wong, J. Y., Shively, J. E., & Wu, A. M. (1996) · PubMed · Cited by 330
Perez, C., Sanchez, A., Putnam, D., Ting, D., Langer, R., & Alonso, M. J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00397-2 · Cited by 313
Oyewumi, M. O., Yokel, R. A., Jay, M., Coakley, T., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.002 · Cited by 296
Green, L. S., Jellinek, D., Bell, C., Beebe, L. A., Feistner, B. D., Gill, S. C., Jucker, F. M., & Janjić, N. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90032-2 · Cited by 284
Davis, F. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00021-2 · Cited by 278
How to Stabilize Phospholipid Liposomes (Using Nanoparticles)
Zhang, L., & Granick, S. (2006) · Nano Letters · doi:10.1021/nl052455y · Cited by 278
Self-citationIrvine, D., Tuerk, C., & Gold, L. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90509-5 · Cited by 266
Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh092 · Cited by 253
Kim, S. H., Jeong, J. H., Chun, K. W., & Park, T. G. (2005) · Langmuir · doi:10.1021/la0502084 · Cited by 242
Khaled, A., Guo, S., Li, F., & Guo, P. (2005) · Nano Letters · doi:10.1021/nl051264s · Cited by 233
Targeted nanoparticle-based drug delivery and diagnosis
Emerich, D. F., & Thanos, C. G. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701231810 · Cited by 228
Tanaka, T., Shiramoto, S., Miyashita, M., Fujishima, Y., & Kaneo, Y. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.050 · Cited by 206
Lee, J. F. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh094 · Cited by 188
Nanoparticle-Based Diagnosis and Therapy
Groneberg, D. A., Giersig, M., Welte, T., & Pison, U. (2006) · Current Drug Targets · doi:10.2174/138945006777435245 · Cited by 158
Development of ligand-targeted liposomes for cancer therapy
Noble, C. O., Kirpotin, D. B., Hayes, M. E., Mamot, C., Hong, K., Park, J. W., Benz, C. C., Marks, J. D., & Drummond, D. C. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.4.335 · Cited by 157
Selection of high affinity RNA ligands to the bacteriophage R17 coat protein
Schneider, D., Tuerk, C., & Gold, L. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90870-p · Cited by 153
In vitro genetic analysis of the Tetrahymena self-splicing intron
Green, R., Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/347406a0 · Cited by 153
Preparation and characterization of carbonyl iron/poly(butylcyanoacrylate) core/shell nanoparticles
Arias, J. L., Gallardo, V., Linares-Molinero, F., & Delgado, Á. V. (2006) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2006.03.005 · Cited by 109
Hansson, M., Ringdahl, J., Robert, A., Power, U. F., Goetsch, L., Nguyen, T. N., Uhlén, M., Ståhl, S., & Nygren, P. (1999) · Immunotechnology · doi:10.1016/s1380-2933(98)00026-8 · Cited by 85
Nanotechnology based drug delivery system(s) for the management of tuberculosis.
Pandey, R., & Khuller, G. K. (2006) · PubMed · Cited by 81
Beekman, K. W., Colevas, A. D., Cooney, K. A., DiPaola, R. S., Dunn, R. L., Gross, M. E., Keller, E. T., Pienta, K. J., Ryan, C. J., Smith, D. C., et al. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.012 · Cited by 80
Brennan, F. R., Shaw, L., Wing, M. G., & Robinson, C. (2004) · Molecular Biotechnology · doi:10.1385/mb:27:1:59 · Cited by 72
Biopharmaceutical drug discovery using novel protein scaffolds
Gill, D. S., & Damle, N. K. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.003 · Cited by 67
Cited by
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Self-citationLipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069
Targeting nanoparticles to cancer
Wang, M., & Thanou, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.005 · Cited by 931
Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy
Yu, M. K., Park, J., & Jon, S. (2012) · Theranostics · doi:10.7150/thno.3463 · Cited by 883
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Metadata
- Authors
- Wang, A. Z., Gu, F., Zhang, L., Chan, J. M., Radovic-Moreno, A., Shaikh, M. R., & Farokhzad, O. C.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2008-07-09
- Volume
- 8
- Issue
- 8
- Pages
- 1063-1070
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2119678257
- Cited by
- 270
- References
- 62
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.